Research And Commercialization Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Amendment No. 1 to Research and Commercialization Agreement (October 1st, 2014)

THIS AMENDMENT No. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (Amendment) is made and entered into effective as of June 30, 2001 (the Amendment Date) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, Medarex), and FIBROGEN, INC., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of Fibrogen, Inc. (collectively, FibroGen). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).

Amendment No. 2 to Research and Commercialization Agreement (October 1st, 2014)

THIS AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (Amendment) is made and entered into effective as of January 28, 2002 (the Amendment Date) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, Medarex), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of FIBROGEN, INC. (collectively, FibroGen). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).

Research and Commercialization Agreement (October 1st, 2014)

THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the Agreement), effective as of July 9, 1998, is entered by and between GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., and Medarex, Inc., a New Jersey corporation, with a principal place of business at 1545 Route 22 East, Annandale, New Jersey 08801 (together Medarex), and FibroGen, Inc. and its wholly-owned subsidiary, FibroPharma, Inc., with a principal place of business at 225 Gateway Boulevard, South San Francisco, California 94080 (together FibroGen).

Research and Commercialization Agreement (August 8th, 2014)

THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the Agreement), effective as of July 9, 1998, is entered by and between GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., and Medarex, Inc., a New Jersey corporation, with a principal place of business at 1545 Route 22 East, Annandale, New Jersey 08801 (together Medarex), and FibroGen, Inc. and its wholly-owned subsidiary, FibroPharma, Inc., with a principal place of business at 225 Gateway Boulevard, South San Francisco, California 94080 (together FibroGen).

Amendment No. 1 to Research and Commercialization Agreement (June 11th, 2014)

THIS AMENDMENT No. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (Amendment) is made and entered into effective as of June 30, 2001 (the Amendment Date) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, Medarex), and FIBROGEN, INC., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of Fibrogen, Inc. (collectively, FibroGen). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).

Amendment No. 2 to Research and Commercialization Agreement (June 11th, 2014)

THIS AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (Amendment) is made and entered into effective as of January 28, 2002 (the Amendment Date) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, Medarex), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of FIBROGEN, INC. (collectively, FibroGen). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).

Research and Commercialization Agreement (January 18th, 2008)

THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the Agreement), effective as of April 6, 2004 (the Effective Date), is entered by and between MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (collectively, Medarex), and CELLDEX THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (Celldex).

Research and Commercialization Agreement (September 22nd, 2004)

This Research and Commercialization Agreement (the Agreement), effective as of April 6, 2004 (the Effective Date), is entered by and between Medarex, Inc., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., (collectively, Medarex), and Celldex Therapeutics, Inc., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (Celldex).

Research and Commercialization Agreement (August 16th, 2004)

This Research and Commercialization Agreement (the Agreement), effective as of April 6, 2004 (the Effective Date), is entered by and between Medarex, Inc., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., (collectively, Medarex), and Celldex Therapeutics, Inc., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (Celldex).

Research and Commercialization Agreement (April 9th, 2004)

THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the "Agreement"), effective as of April 6, 2004 (the "Effective Date"), is entered by and between MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (collectively, "Medarex"), and CELLDEX THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 ("Celldex").

Medarex – Amendment No. 1 to Research and Commercialization Agreement (January 26th, 2000)
Medarex – Research and Commercialization Agreement (January 26th, 2000)
Medarex – Research and Commercialization Agreement (January 26th, 2000)
Medarex – Research and Commercialization Agreement (January 26th, 2000)
Medarex – Evaluation, Research and Commercialization Agreement (February 26th, 1999)